- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 17.03. | Rapid Micro Biosystems stellt auf KeyBanc-Forum strategische Wachstumspläne vor | 5 | Investing.com Deutsch | ||
| 12.03. | RAPID MICRO BIOSYSTEMS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| RAPID MICRO BIOSYSTEMS Aktie jetzt für 0€ handeln | |||||
| 12.03. | RAPID MICRO BIOSYSTEMS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 12.03. | Rapid Micro Biosystems outlines $37M-$41M 2026 revenue target amid record system placements and margin expansion drive | 1 | Seeking Alpha | ||
| 12.03. | Rapid Micro Biosystems: Starker Umsatz, aber höherer Verlust im Q4 2025 - Aktie bricht vorbörslich ein | 8 | Investing.com Deutsch | ||
| 12.03. | Rapid Micro Biosystems reports mixed Q4 results; introduces FY26 outlook | 3 | Seeking Alpha | ||
| 12.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct Platform | 1.026 | GlobeNewswire (Europe) | LEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission critical automation... ► Artikel lesen | |
| 10.03. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum | 2 | GlobeNewswire (USA) | ||
| 24.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 | 1 | GlobeNewswire (USA) | ||
| 12.02. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 14.01. | After-Hours Biotech Rally: SXTC, RPID, TGTX Lead Gains On Revenue Updates, And FDA Milestones | 627 | AFX News | BEIJING (dpa-AFX) - Several biotechnology and pharmaceutical names posted notable gains in Tuesday's after-hours trading session, driven by corporate updates and investor enthusiasm around clinical... ► Artikel lesen | |
| 13.01. | Rapid Micro Biosystems reports preliminary fourth quarter revenue | 2 | Seeking Alpha | ||
| 13.01. | Rapid Micro Biosystems reports Q4 results | 1 | Seeking Alpha | ||
| 13.01. | Rapid Micro Biosystems reports 37% revenue growth in Q4 2025 | 4 | Investing.com | ||
| 13.01. | Rapid Micro Biosystems, Inc.: Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue | 1.100 | GlobeNewswire (Europe) | Fourth quarter 2025 total revenue expected to be approximately $11.3 million, representing growth of approximately 37% compared to the prior-year period.Received record multi-system order in the fourth... ► Artikel lesen | |
| 13.01. | RAPID MICRO BIOSYSTEMS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.25 | Rapid Micro Biosystems: GrowthDirect-Plattform im Fokus der Wachstumsstrategie | 2 | Investing.com Deutsch | ||
| 07.11.25 | Rapid Micro Biosystems raises 2025 revenue guidance to at least $33M amid record multi-system order and accelerating margin improvement | 2 | Seeking Alpha | ||
| 07.11.25 | RAPID MICRO BIOSYSTEMS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| EVOTEC | 5,350 | -0,93 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Evotec auf "Outperform" mit einem Kursziel von 10 Euro belassen. Charles Weston passte seine Prognosen und das Bewertungsmodell... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,700 | -1,80 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 5,020 | +24,57 % | What's Going On With Enveric Biosciences Stock On Friday? | ||
| NUVALENT | 104,53 | -3,28 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| FIRST TRACKS BIOTHERAPEUTICS | 18,160 | -4,47 % | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 29,760 | +2,62 % | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004... ► Artikel lesen |
Das Unternehmen RAPID MICRO BIOSYSTEMS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,030 (+1,33 %) liegt der Kurs bei 2,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPID MICRO BIOSYSTEMS INC finden Sie auf Wallstreet Online.